We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Oncosil Medical Ltd | ASX:OSL | Australian Stock Exchange | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.005 | 0.005 | 0.006 | 0.006 | 0.005 | 0.006 | 1,345,207 | 05:10:43 |
RNS Number:1943N O&L Acquisition PLC 04 July 2003 4 July 2003 This announcement is not for release, publication or distribution in or into the United States, Canada, Australia or Japan RECOMMENDED OFFER by ALTIUM CAPITAL LIMITED on behalf of O&L ACQUISITION PLC to acquire the whole of the issued and to be issued share capital of OSBORNE & LITTLE PLC OFFER DOCUMENT POSTED In connection with the announcement today of the recommended offer by Altium Capital, on behalf of O&L Acquisition, to acquire the whole of the issued and to be issued share capital of Osborne & Little, O&L Acquisition announces that the Offer Document and Form of Acceptance relating to the Offer have been posted to Osborne & Little Shareholders today. The Offer will be open for acceptance until 3.00 p.m. on 25 July 2003. Terms defined in the Offer Document dated 4 July 2003 have the same meaning in this announcement. Enquiries: Garry Levin Tel: 020 7484 4040 Mark Dickenson Alexander Church Altium Capital Limited Sir Peter Osborne (Chairman) Tel: 020 8675 2255 Peter Soar (Finance Director) Osborne & Little PLC The Offer (including the Share Alternative) is not being made, directly or indirectly, in, into or from the United States, or by use of the United States mails, or by any means or instrumentality (including, without limitation, facsimile transmission, telex, telephone or e-mail) of United States interstate or foreign commerce, or any facility of a national securities exchange of the United States, Canada, Australia or Japan. Accordingly, this announcement, copies of this announcement and any related documents are not being and must not be mailed or otherwise distributed or sent in, into or from the United States, Canada, Australia or Japan and persons receiving this document and any related documents (including custodians, nominees and trustees) must not mail or otherwise forward, distribute or send them in, into or from the United States, Canada, Australia or Japan. All Osborne & Little Shareholders (including nominees, trustees or custodians) who would, or otherwise intend to forward this document, should inform themselves about and observe any applicable requirement. Altium Capital, which is regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for O&L Acquisition as financial adviser within the meaning of the rules of the Financial Services Authority and for no one else in connection with the Offer and is not advising any other person or treating any other person as its client in relation thereto and will not be responsible to anyone other than O&L Acquisition for providing the protections afforded to clients of Altium Capital, or for giving advice to any other person in relation to the Offer, the contents of this announcement or any other matter referred to herein. This information is provided by RNS The company news service from the London Stock Exchange END ODPRIMITMMIMBJJ
1 Year Oncosil Medical Chart |
1 Month Oncosil Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions